Susquehanna International Group
ACRS icon

Susquehanna International Group’s Aclaris Therapeutics ACRS Stock Holding History

Susquehanna International Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$506K Buy
+134,900
New +$455K ﹤0.01% 9636
2025
Q1 		– Sell
-91,300
Closed -$226K – 12372
2024
Q4 		$226K Buy
+91,300
New +$227K ﹤0.01% 10451
2024
Q2 		– Sell
-15,700
Closed -$19.5K – 11922
2024
Q1 		$19.5K Sell
15,700
-6,400
-29% -$7.63K ﹤0.01% 11824
2023
Q4 		$23.2K Sell
22,100
-51,900
-70% -$158K ﹤0.01% 11946
2023
Q3 		$507K Sell
74,000
-34,300
-32% -$293K ﹤0.01% 8189
2023
Q2 		$1.12M Sell
108,300
-61,700
-36% -$558K ﹤0.01% 6410
2023
Q1 		$1.38M Buy
170,000
+150,300
+763% +$1.91M ﹤0.01% 6015
2022
Q4 		$310K Buy
19,700
+900
+5% +$14.5K ﹤0.01% 9021
2022
Q3 		$296K Buy
18,800
+4,900
+35% +$77.2K ﹤0.01% 9824
2022
Q2 		$194K Buy
13,900
+3,000
+28% +$42K ﹤0.01% 10679
2022
Q1 		$188K Buy
+10,900
New +$149K ﹤0.01% 11303
2021
Q3 		– Sell
-75,000
Closed -$1.32M – 12652
2021
Q2 		$1.32M Sell
75,000
-25,800
-26% -$586K ﹤0.01% 6999
2021
Q1 		$2.54M Buy
100,800
+89,800
+816% +$1.76M ﹤0.01% 5342
2020
Q4 		$71K Buy
+11,000
New +$46.4K ﹤0.01% 10638
2019
Q4 		– Sell
-10,300
Closed -$11K – 9615
2019
Q3 		$11K Sell
10,300
-36,200
-78% -$51.4K ﹤0.01% 10009
2019
Q2 		$102K Buy
46,500
+1,000
+2% +$5.45K ﹤0.01% 9593
2019
Q1 		$273K Buy
+45,500
New +$302K ﹤0.01% 7378
2018
Q3 		– Sell
-18,000
Closed -$359K – 9097
2018
Q2 		$359K Buy
18,000
+3,500
+24% +$64.7K ﹤0.01% 7480
2018
Q1 		$254K Sell
14,500
-45,900
-76% -$973K ﹤0.01% 7907
2017
Q4 		$1.49M Buy
60,400
+46,700
+341% +$1.14M ﹤0.01% 4469
2017
Q3 		$354K Buy
+13,700
New +$367K ﹤0.01% 7108

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Susquehanna International Group's ACRS Position: Q1 2026 in Review

Susquehanna International Group reduced its Aclaris Therapeutics (ACRS) stake by 59% in Q1 2026, selling an estimated $1.81M and leaving 379,930 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #7018.

Susquehanna International Group first reported a position in ACRS in Q1 2017 and has held it in 28 quarters since. The position peaked at $11.3M in Q1 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Susquehanna International Group held 379,930 shares of Aclaris Therapeutics worth $1.42M as of Q1 2026.
  • Susquehanna International Group sold 536,916 Aclaris Therapeutics shares in Q1 2026, an estimated $1.81M.
  • Aclaris Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7018 holding.
  • Susquehanna International Group first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 28 quarters since.
  • Susquehanna International Group's Aclaris Therapeutics position peaked at $11.3M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.